

# HOW WE DO PSMA Theranostics

1<sup>ST</sup> - 2<sup>ND</sup> APRIL 2022

ProstIC Preceptorship 2022

From Melbourne to the World

Friday		
0730 - 0815	Registration	
0815 - 0830	Official welcome	
0830 - 1030	<b>Session 1: What is the role of PSMA PET/CT in early stage prostate cancer</b>	<i>Session Chair: Prof. Louise Emmett</i>  <i>Co-Chair: A/Prof. Shankar Siva</i>
	When do I use PSMA PET/CT in staging and biochemical recurrence: urologists perspective	<i>Dr. Renu Eapen</i>
	PSMA PET for staging: current evidence base	<i>Dr. Su-Faye Lee</i>
	Clinical trial data uses CT/bone scanning: how do we manage patients in the PSMA PET era? (focus of "non-metastatic" & high-volume/low-volume)	<i>Prof. Wolfgang Fendler</i>
	Spoilt for choice with Ga-68 PSMA-11, F-18 DCFPyL & F-18 PSMA1007: is there a difference?	<i>Prof. Tom Hope</i>
	Best practice PSMA PET/CT: accepted use criteria, standardised reporting	<i>Prof. Tom Hope</i>
	How PSMA PET/CT can improve delivery of radiotherapy	<i>A/Prof. George Hruby</i>
	Will PSMA PET/CT replace mpMRI for diagnosis of prostate cancer?	<i>A/Prof. Daniel Moon</i>
	PSMA PET/CT: how we interpret changes in uptake intensity following ADT?	<i>Prof. Louise Emmett</i>
	Q&A	<i>All speakers</i>

# HOW WE DO PSMA Theranostics

1<sup>ST</sup> - 2<sup>ND</sup> APRIL 2022

ProstIC Preceptorship 2022

From Melbourne to the World

1030 - 1100	Morning tea	
1100 - 1230	<b>Session 2: MDT</b>	<i>Session Chair: Prof. Michael Hofman</i>  <i>Co-Chair: A/Prof. Sze-Ting Lee</i>
	MDT Panel - PSMA PET/CT "live" cases: pearls and pitfalls	<i>Peter Mac MDT Panel</i>
1230 - 1330	Lunch	
1330 - 1530	<b>Session 3: Evidence-based PSMA radioligand therapy</b>	<i>Session Chair: Prof. Mark Rosenthal</i>  <i>Co-Chair: Ms Elizabeth Medhurst</i>
	Guiding current practice with best available evidence: TheraP and VISION	<i>Dr. Aravind Ravi Kumar</i>
	How I Select Patients	<i>Prof. Michael Hofman</i>
	Aussie leading the way with Investigator Initiated Trials: emerging combinations in mCRPC <i>"Novel Radionuclide Treatment Combinations"</i>	<i>A/Prof. Shahneen Sandhu</i>
	Multi-centre trials in Australia: collaborative approach	<i>A/Prof. Roslyn Francis</i>
	Global clinical trial landscape: trials underway or about to commence	<i>Prof. Tom Hope</i>
	Navigating gaps in level 1 evidence: what do the experts do in tricky situations	<i>Prof. Silke Gillissen</i>

# HOW WE DO PSMA Theranostics

## 1<sup>ST</sup> - 2<sup>ND</sup> APRIL 2022

### ProstIC Preceptorship 2022

From Melbourne to the World

	Theranostics Landscape: What's required for optimal patient outcomes  <i>"Theranostics Landscape: Partnering for optimal patient outcomes"</i>	<i>A/Prof. Sze-Ting Lee</i>
	Next generation research - How I do it.	<i>Prof. Veeru Kasivisvanathan</i>
	Q&A	<i>All speakers</i>
1530- 1600	Afternoon Break	
1600 - 1730	<b>Session 4: The Theranostic Suite: how we run it from 7 perspectives</b>	<i>Session Chair: Prof. Stephen Stuckey</i>  <i>Co-Chair: Ms Jenny Marcen</i>
	Nuclear medicine technologist: administration and post therapy imaging	<i>Mr Mark Scalzo</i>
	Nuclear medicine specialist: more than just a service provider	<i>A/Prof. Grace Kong</i>
	Nurse specialist: fully integrated	<i>Ms. Elizabeth Medhurst</i>
	Medical physicist <i>"Dosimetry in Lu-PSMA Therapy: Practical and Technical Considerations"</i>	<i>Dr. Price Jackson</i>
	Medical oncologist: bringing it all together	<i>A/Prof. Arun Azad</i>
	Radiopharmacy: how the kitchen operates - a unique medicinal environment	<i>Dr. Mohammad Haskali</i>
	Patient perspective: what I value	
	Q&A	<i>Panel</i>

# HOW WE DO PSMA Theranostics

1<sup>ST</sup> - 2<sup>ND</sup> APRIL 2022

ProSTIC Preceptorship 2022

From Melbourne to the World


1900 - 2230	Conference Dinner	
<b>Saturday</b>		
0800 - 0900	<b>Session 5: The art of PSMA theranostics</b>	Session Chair: <i>Prof. Ian Davis</i> Co-Chair: <i>Ms Julia Keenan</i>
	How I sequence LuPSMA in the landscape of increasing options for mCRPC?	<i>Dr. Louise Kostos</i>
	Prognostic and predictive imaging biomarkers: PSMA and FDG PET/CT	<i>Dr. James Buteau</i>
	Future PSMA: how deep learning artificial intelligence will change the way you work	<i>Mr. Lachlan McIntosh</i>
	Next generation PSMA: Actinium and beyond	<i>Dr. Matthias Eiber</i>
	Deep Learning of PSMA PET: will AI replace human?	<i>Dr. Andrei Gafita</i>
	Other biomarkers in prostate cancer: CTCs, ctDNA and beyond	<i>Dr. Heidi Fettke</i>
0900-1030	<b>Session 6: MDT</b>	Session Chair: <i>Prof. Declan Murphy</i>
	Multi-disciplinary team discussion of complex cases, complex decisions	
1030 - 1100	Morning Tea	
1100 -1230	<b>Session 7: The Barry Elderfield Lecture</b>	Session Chair: <i>TB</i>
	HARDtalk - in depth interview with hard hitting questions covering all things PSMA .	<i>Prof. Michael Hofman, Prof</i>

# HOW WE DO PSMA Theranostics

## 1<sup>ST</sup> - 2<sup>ND</sup> APRIL 2022

### ProstIC Preceptorship 2022

From Melbourne to the World

	In a world first, join Professor Tom Hope, Professor Michael Hofman and Professor Declan Murphy, as they HARDtalk the hot topics and hard hitting questions of "The current state of PSMA" and "What's coming next".	<i>Declan Murphy &amp; Prof. Tom Hope</i>
1230	Conference close and thanks	
1230 - 1330	Lunch	
1330 - 1500	<b>Session 8: Consumer</b>	Session Chair: <i>Prof. Jeff Dunn</i>
	<p>Ask the Experts – Representation: Q&amp;A &amp; Panel discussion</p>  <p>Prostate Cancer Foundation of Australia</p> <p>This session is proudly presented in collaboration with the <a href="#">Prostate Cancer Foundation of Australia</a>.</p>	<i>Consumer Advocates</i>
1500 - 1530	Wrap up	